Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.
Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 18, 11, 1, 1, 15, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Foot Ulcers - Overview
Diabetic Foot Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Foot Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
Diabetic Foot Ulcers - Drug Profiles
3K3A-APC - Drug Profile
Product Description
Mechanism Of Action
Amesanar - Drug Profile
Product Description
Mechanism Of Action
AP-185 - Drug Profile
Product Description
Mechanism Of Action
APO-2 - Drug Profile
Product Description
Mechanism Of Action
ASCP-02 - Drug Profile
Product Description
Mechanism Of Action
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
AV-001 - Drug Profile
Product Description
Mechanism Of Action
BB-101 - Drug Profile
Product Description
Mechanism Of Action
BFP-001 - Drug Profile
Product Description
Mechanism Of Action
BFP-101 - Drug Profile
Product Description
Mechanism Of Action
Biologic for Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Diabetic Foot Ulcer - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
CHF-6467 - Drug Profile
Product Description
Mechanism Of Action
Corlicyte - Drug Profile
Product Description
Mechanism Of Action
CSA-144 - Drug Profile
Product Description
Mechanism Of Action
CTX-001 - Drug Profile
Product Description
Mechanism Of Action
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
CYP-006TK - Drug Profile
Product Description
Mechanism Of Action
diperoxochloric acid - Drug Profile
Product Description
Mechanism Of Action
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
Drug for Diabetic Foot Ulcer - Drug Profile
Product Description
Mechanism Of Action
ENERGIF-703 - Drug Profile
Product Description
Mechanism Of Action
Epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
EscharEx - Drug Profile
Product Description
Mechanism Of Action
EscharEx Second Generation - Drug Profile
Product Description
Mechanism Of Action
esmolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
FGF-1 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Diabetic Foot Ulcers and Wound - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
Product Description
Mechanism Of Action
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
MR-MC-01 - Drug Profile
Product Description
Mechanism Of Action
MSC Exosomal Topical Suspension - Drug Profile
Product Description
Mechanism Of Action
MT-003 - Drug Profile
Product Description
Mechanism Of Action
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
NORS-2791 - Drug Profile
Product Description
Mechanism Of Action
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
OLX-106 - Drug Profile
Product Description
Mechanism Of Action
PCSPH-08 - Drug Profile
Product Description
Mechanism Of Action
PP-2351 - Drug Profile
Product Description
Mechanism Of Action
RECCE-327 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Human Platelet-Derived Growth Factor Gel - Drug Profile
Product Description
Mechanism Of Action
recombinant plasminogen - Drug Profile
Product Description
Mechanism Of Action
rhPDGF-BB - Drug Profile
Product Description
Mechanism Of Action
ropocamptide - Drug Profile
Product Description
Mechanism Of Action
RP-557 - Drug Profile
Product Description
Mechanism Of Action
rusalatide acetate - Drug Profile
Product Description
Mechanism Of Action
SER-190 - Drug Profile
Product Description
Mechanism Of Action
SLIF-06 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit NOX for Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Infected Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
SR-0379 - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Diabetic Foot Ulcers, Injuries and Liver Diseases - Drug Profile
Product Description
Mechanism Of Action
Stempeucel - Drug Profile
Product Description
Mechanism Of Action
suramin - Drug Profile
Product Description
Mechanism Of Action
SymHeal - Drug Profile
Product Description
Mechanism Of Action
tobramycin + triclosan - Drug Profile
Product Description
Mechanism Of Action
TOPN-53 - Drug Profile
Product Description
Mechanism Of Action
TP-102 - Drug Profile
Product Description
Mechanism Of Action
TTAX-01 - Drug Profile
Product Description
Mechanism Of Action
TWB-103 - Drug Profile
Product Description
Mechanism Of Action
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
WF-10 - Drug Profile
Product Description
Mechanism Of Action
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Featured News & Press Releases
Sep 27, 2022: Recce Pharmaceuticals announces expansion and acceleration of clinical programs
Sep 26, 2022: CellResearch to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles
Sep 19, 2022: Ceria Therapeutics awarded a $300,000 SBIR Grant to advance development of a novel treatment of non-healing diabetic foot ulcers
Sep 16, 2022: CellResearch (CRC) announces positive results of phase I study for CorLiCyte
Aug 10, 2022: Promore Pharma granted EU patent regarding treatment of chronic wounds
Jul 07, 2022: Destiny Pharma announces publication of XF-73 drug synergy data
Apr 21, 2022: Cynata advances clinical trial in Diabetic Foot Ulcers
Apr 12, 2022: MediWound's EscharEx highlighted in poster and oral presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Apr 05, 2022: Lakewood-Amedex enrolls first patient in phase 2 clinical trial for patients with chronic diabetic foot Ulcers (cDFU
Mar 29, 2022: MediWound to present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Dec 22, 2021: Cynata commences DFU clinical trial
Nov 04, 2021: TechnoPhage announces first clinical safety results with innovative biological product TP-102
Oct 22, 2021: Helixmith announces phase 3 study results of novel gene therapy treatment for diabetic foot ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer Conference (DFCon)
Aug 24, 2021: Another take on TP-102 Phase I/IIa Clinical Trial by Jornal Expresso
Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Foot Ulcers, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diabetic Foot Ulcers - Dormant Projects, 2022
Diabetic Foot Ulcers - Discontinued Products, 2022
List of Figures
Number of Products under Development for Diabetic Foot Ulcers, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
